v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total revenue $ 4,298,000 $ 3,618,000 $ 15,348,000 $ 16,073,000
Operating expenses:        
Research and development 19,622,000 15,249,000 70,667,000 33,946,000
General and administrative 7,547,000 4,509,000 19,606,000 14,049,000
Loss on impairment of in-process research and development 0 22,123,000 0 22,123,000
Total operating expenses 27,169,000 41,881,000 90,273,000 70,118,000
Loss from operations 22,871,000 38,263,000 74,925,000 54,045,000
Interest and other income, net 167,000 396,000 925,000 1,449,000
Interest and other expense, net (521,000) (353,000) (1,229,000) (947,000)
Loss on extinguishment of debt 0 0 (1,237,000) 0
Change in fair value of warrant liabilities 0 1,000 0 3,000
Loss before provision for income taxes 23,225,000 38,219,000 76,466,000 53,540,000
Provision for income taxes 0 0 5,000 0
Net loss 23,225,000 38,219,000 76,471,000 53,540,000
Net loss attributable to common shareholders $ 23,225,000 $ 38,219,000 $ 76,471,000 $ 53,540,000
Net loss per share attributable to common shareholders:        
Basic and diluted $ 0.47 $ 1.03 $ 1.63 $ 1.45
Weighted average number of shares used in net loss per share calculations:        
Basic and diluted 49,026,499 36,937,912 46,808,437 36,832,966
Research And Development Revenue | Other        
Total revenue $ 2,732,000 $ 284,000 $ 7,176,000 $ 284,000
Research And Development Revenue | Related Party        
Total revenue 1,566,000 2,903,000 4,962,000 14,527,000
Grant        
Total revenue $ 0 $ 431,000 $ 3,210,000 $ 1,262,000

Source